[junkie-button url=”http://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
[junkie-alert style=”red”] ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”) announced today completion of all internal processes to initiate clinical studies and the initial production of its “soft suit” exoskeleton design for stroke patients. Called “Restore,” the new system is the first product in the company’s expansion into new technologies that will serve mobility-challenged patient communities. This design is targeted to serve the stroke rehabilitation community. [/junkie-alert]
This lightweight design of the Restore system was specifically configured for stroke survivors who face mobility issues. The system is designed to provide real-time adjustable walking assistance for stroke patients in a compact, light, modular soft exosuit structure. It utilizes some of the key features from structural exoskeleton designs in assisting rehabilitation, with the advancement of being able to achieve these goals without the size, structure and expense of current designs.
CEO of ReWalk Larry Jasinski said, “Achieving successful laboratory testing and design review processes with the Restore system is a milestone that advances our efforts for commercialization.” He went on to say, “The potential of these soft suit designs to expand the utilization of robotic technologies initially with stroke patients in rehab—and in the future for community use—is meaningful. Research into applications, such as multiple sclerosis and Parkinson’s Disease is the next horizon.”
The company reports the Restore transmits power to key joints of the legs with cable technologies, powered with software and mechanics that are similar to the technologies used in the ReWalk exoskeleton system for individuals with spinal cord injury. The cables are connected to fabric-based designs that attach to the legs and foot, thus lending the name “soft suit.”
Anticipated delivery of a commercial Restore soft suit is targeted for 2018. ReWalk plans to commercialize use of the Restore system in Europe and the United States after receiving CE and FDA clearance, respectively, to market the device. The company intends to apply for CE and FDA clearances in mid-2018; CE and FDA clearance applications will be submitted as clinical and laboratory testing are completed in the coming months.